Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gut that can lead to severe gastrointestinal symptoms, malnutrition, and complications such as fistulas and cancer. Mesenchymal stem/stromal cells (MSCs) are being investigated as a novel therapy for IBD and have been demonstrated to be safe and effective for perianal fistulizing Crohn’s disease (PFCD). This systematic review aims to present the most recent studies on the safety and efficacy of MSC therapy in IBD. A detailed search strategy of clinical trials on MSCs and IBD was performed on PubMed, with 32 studies selected for inclusion in this review. The newest studies on local MSC injection for PFCD continue to support long-term efficacy while maintaining a favorable safety profile. The evidence for systemic MSC infusion in luminal IBD remains mixed due to marked methodological heterogeneity and unclear safety profiles. Although further studies are needed to better establish the role of this novel treatment modality, MSCs are proving to be a very exciting addition to the limited therapies available for IBD.

中文翻译：

---

间充质干细胞/间质干细胞治疗炎症性肠病的疗效和安全性：最新系统评价。

炎症性肠病（IBD）是肠道的一种慢性炎症性疾病，可导致严重的胃肠道症状，营养不良以及诸如瘘管和癌症的并发症。间充质干/基质细胞（MSCs）作为一种IBD的新疗法正在研究中，已被证明对于肛周瘘管克罗恩病（PFCD）安全有效。本系统综述旨在介绍有关IBD中MSC治疗的安全性和有效性的最新研究。在PubMed上进行了关于MSC和IBD的临床试验的详细搜索策略，选择了32项研究纳入本评价。有关用于PFCD的局部MSC注射的最新研究继续支持长期疗效，同时保持良好的安全性。由于明显的方法学异质性和不清楚的安全性，在腔内IBD中全身性MSC输注的证据仍然混杂。尽管需要进一步研究以更好地确立这种新型治疗方式的作用，但事实证明，MSCs是IBD可用有限疗法的非常令人兴奋的补充。